SEC Form 4 · accession 0001562180-18-004443
Syndax Pharmaceuticals Inc · SNDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael L. Meyers
Officer — SVP, Chief Medical Officer
Period of report
Oct 30, 2018
Accepted (ET)
Nov 7, 2018 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001395937
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 30, 2018 | P | 200 | $4.79 | A | 2,398 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 2,198 shares acquired under the Syndax Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan on 7/31/2018.